Autolus has a lot of CAR-T candidates heading for clinical trials and has teamed up with software company Vineti to try to bring them to market more efficiently. Three-year-old Vineti, co-founded by GE Ventures and Mayo Clinic Ventures, has developed cloud-based software to automate and orchestrate the many steps involved in the production and delivery of cell and gene therapies. Autolus said it will use the software across its portfolio of clinical-stage T cell therapies, which includes five blood cancer and one solid tumor product. Source: Fierce Biotech 25/2/2019